Related Experiment Video
Updated: Jun 14, 2026

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity
Published on: May 1, 2018
[Development of anti-tumor blood vessel antibodies by phage display method]
Takuya Yamashita1, Naoki Utoguchi, Ryo Suzuki
1Department of Biopharmaceutics, Teikyo University, Kanagawa, Japan. t-yamashita@nibio.go.jp
Abstract:
Tumor blood vessels are essential for tumor growth. Therefore, these blood vessels are potential targets for anti-cancer therapy. The purpose of this study is to develop anti-tumor endothelial cell (TEC) antibodies for delivering anti-cancer agents or drugs. To achieve this goal, we utilized the phage antibody display library method to create monoclonal antibodies in vitro. Accordingly, we developed anti-TEC antibodies from an single chain Fv fragment (scFv) phage display library prepared using the Fv genes amplified from the mRNAs isolated from the TEC-immunized mice. The size of the phage antibody library prepared from the mRNA of the TEC-immunized mice was approximately 1.3x10(7) CFU. To select and enrich for the phages displaying the anti-TEC antibodies, cell panning was performed first using the TEC followed by subtractive panning using the normal endothelial cell. After five cycles of panning, the affinity of bound phage clones increased approximately 10 000 folds. Subsequently, clones isolated from the post-panning output library were tested for their antigen-specificity by ELISA and western blotting. One of the scFv phage clones showing antigen-specificity recognized only TEC in vitro, and when injected into the Colon26 bearing mice, this clone accumulated more on the tumor tissue than the wild type phage. These results suggest that the isolated an antibody and this clone's target molecule could be potentially useful for novel anti-tumor therapies.
Insights
Researchers developed novel tumor endothelial cell (TEC) antibodies using phage display technology. These targeted antibodies show potential for delivering anti-cancer drugs, offering a new approach in cancer therapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Context:
- Tumor blood vessels are critical for cancer progression and represent a key therapeutic target.
- Developing targeted therapies that specifically attack tumor vasculature is a significant challenge in oncology.
Purpose:
- To generate specific monoclonal antibodies targeting tumor endothelial cells (TECs).
- To create a phage antibody display library for isolating TEC-specific single-chain variable fragments (scFvs).
Summary:
- A phage antibody display library of approximately 1.3x10^7 CFU was constructed from TEC-immunized mice.
- Cell panning and subtractive panning enriched for TEC-specific scFv phage clones, increasing binding affinity by 10,000-fold.
- One selected scFv clone demonstrated high specificity for TECs in vitro and accumulated preferentially in tumor tissues in vivo.
Impact:
- The isolated TEC-specific antibody and its target molecule show promise for developing novel anti-cancer therapies.
- This approach could lead to more effective drug delivery systems targeting tumor vasculature.
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

